EAGLE PHARMACEUTICALS, INC. Quarterly Debt-to-equity in % from Q3 2020 to Q2 2023

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Eagle Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q2 2023.
Eagle Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2023 was 67.8 %, a 39.6% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2023	67.8	+19.3	+39.6%	Jun 30, 2023
Q1 2023	67.9	+26.2	+63%	Mar 31, 2023
Q4 2022	62.6	+24.3	+63.3%	Dec 31, 2022
Q3 2022	55.7	+19.2	+52.5%	Sep 30, 2022
Q2 2022	48.6	+10.9	+28.8%	Jun 30, 2022
Q1 2022	41.7	+2.93	+7.57%	Mar 31, 2022
Q4 2021	38.3	-16.3	-29.8%	Dec 31, 2021
Q3 2021	36.5	-19.7	-35.1%	Sep 30, 2021
Q2 2021	37.7			Jun 30, 2021
Q1 2021	38.7			Mar 31, 2021
Q4 2020	54.6			Dec 31, 2020
Q3 2020	56.2			Sep 30, 2020

* An asterisk sign (*) next to the value indicates that the value is likely invalid.